Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Factors associated with progression to critical illness in 28 days among COVID-19 patients: results from a tertiary care hospital in Istanbul, Turkey

Sili et al., medRxiv, doi:10.1101/2020.10.09.20209775
Oct 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Analysis of hospitalized patients in Turkey showing HCQ was given to 99.2% of patients and the incidence of critical illness was lower than most studies. Authors note "whether HCQ administration lowered the rates of critical illness development is beyond the scope of this study." There is no comparison with a control group.
Sili et al., 11 Oct 2020, Turkey, preprint, 21 authors.
This PaperHCQAll
Factors associated with progression to critical illness in 28 days among COVID-19 patients: results from a tertiary care hospital in Istanbul, Turkey
MD Uluhan Sili, Pinar Ay, Ahmet Topuzoglu, Elif Huseyin Bilgin, Elif Tukenmez Tigen, Buket Erturk Sengel, Dilek Yagci Caglayik, Baran Balcan, Sehnaz Derya Kocakaya, Sehnaz Olgun Yildizeli, Fethi Gul, Beliz Bilgili, Rabia Can Sarinoglu, Aysegul Karahasan Yagci, Lutfiye Mulazimoglu Durmusoglu, Emel Eryuksel, Zekaver Odabasi, Haner Direskeneli, Sait Karakurt, Ismail Cinel, Volkan Korten
Background Coronavirus disease 2019 quickly spread worldwide to become a pandemic. This study aimed to define the predictors of critical illness development within 28 days postadmission. Methods We conducted a prospective cohort study including 477 PCR-positive COVID-19 patients admitted to a tertiary care hospital in Istanbul from March 12 to May 12, 2020. The development of critical illness, e.g., invasive mechanical ventilation and/or death, was followed for a period of 28 days postadmission. Demographic characteristics, number of comorbidities, illness severity at admission defined by the WHO scale, vital signs, laboratory findings and period of admission to the hospital were independent variables. Cox proportional hazards analysis was performed, and the C-index was calculated. Results The median (IQR) age of the cohort was 55.0 (44.0-67.0) years, and 50.1% were male. The most common presenting symptoms were cough, dyspnea and fatigue. Overall, 65.2% of the patients had at least one comorbidity. Hydroxychloroquine was given to 99.2% of the patients. Critical illness developed in 45 (9.4%; 95% CI: 7.0%-12.4%) patients. In the multivariable analysis, age (HR: 1.05, p<0.001), number of comorbidities (HR: 1.33, p=0.02), procalcitonin ≥0.25 µg/L (HR: 2.12, p=0.03) and LDH ≥350 U/L (HR: 2.04, p=0.03) were .
Allenbach, Saadoun, Maalouf, Multivariable prediction model of intensive care unit transfer and death: a French prospective cohort study of COVID-19 patients, medRxiv, doi:10.1101/2020.05.04.20090118
Anesi, Halpern, Delgado, Covid-19 related hospital admissions in the United States: needs and outcomes, BMJ, doi:10.1136/bmj.m2082
Barnes, Burnett, Allen, Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum, J Thromb Thrombolysis, doi:10.1007/s11239-020-02138-z
Bhargava, Fukushima, Levine, Predictors for Severe COVID-19 Infection, Clin Infect Dis, doi:10.1093/cid/ciaa674
Cen, Chen, Shen, Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019-a multi-centre observational study, Clin Microbiol Infect, doi:10.1016/j.cmi.2020.05.041
Galloway, Norton, Barker, A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study, J Infect, doi:10.1016/j.jinf.2020.05.064
Gong, Ou, Qiu, A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19) : A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China, Clin Infect Dis, doi:10.1093/cid/ciaa443
Goyal, Choi, Pinheiro, Clinical Characteristics of Covid-19 in New York City, N Engl J Med, doi:10.1056/NEJMc2010419
Korber, Fischer, Gnanakaran, Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2, bioRxiv, doi:10.1101/2020.04.29.069054
Lechien, Chiesa-Estomba, Place, Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019, J Intern Med, doi:10.1111/joim.13089
Liang, Liang, Ou, Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19, JAMA Intern Med, doi:10.1001/jamainternmed.2020.2033
Paliani, Cardona, COVID-19 and hydroxychloroquine: Is the wonder drug failing?, Eur J Intern Med, doi:10.1016/j.ejim.2020.06.002
Petrilli, Jones, Yang, Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study, BMJ, doi:10.1136/bmj.m1966
Potere, Valeriani, Candeloro, Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and metaanalysis, Crit Care, doi:10.1186/s13054-020-03022-1
Rivera-Izquierdo, Del, Valero-Ubierna, Rd, Sociodemographic, clinical and laboratory factors on admission associated with COVID-19 mortality in hospitalized patients: A retrospective observational study, PLoS One, doi:10.1371/journal.pone.0235107
Rodriguez-Morales, Cardona-Ospina, Gutierrez-Ocampo, Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101623
Singer, Deutschman, Seymour, The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), JAMA, doi:10.1001/jama.2016.0287
Weissman, Crane-Droesch, Chivers, Locally Informed Simulation to Predict Hospital Capacity Needs During the COVID-19 Pandemic, Ann Intern Med, doi:10.7326/M20-1260
Wiersinga, Rhodes, Cheng, Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review, JAMA, doi:10.1001/jama.2020.12839
Wu, Mcgoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648
Wynants, Van Calster, Collins, Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal, BMJ, doi:10.1136/bmj.m1328
Xu, Tian, Luo, Risk factors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational study, Theranostics, doi:10.7150/thno.46833
Yao, Lu, Chen, Patient-derived mutations impact pathogenicity of SARS-CoV-2, medRxiv, doi:10.1101/2020.04.14.20060160
Zheng, Peng, Xu, Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis, J Infect, doi:10.1016/j.jinf.2020.04.021
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop